论文部分内容阅读
目的探讨莫西沙星方案治疗广泛耐药肺结核的临床效果。方法85例耐药涂阳,药敏试验结果左氧氟沙星、对氨水杨酸钠敏感,其余所有都耐药患者随机分为治疗组及对照组,除左氧氟沙星和莫西沙星不同外,其他用药均相同。结果治疗组痰菌阴转率2、4、6、18个月分别为41.9%、60.5%、88.4%、95.3%;对照组痰菌阴转率分别为14.3%、31.0%、57.1%、71.4%。空洞闭合率分别为97.7%、85.7%(P<0.05),经比较差异有统计学意义(P<0.05)。结论莫西沙星治疗广泛耐多药肺结核疗效优于左氧氟沙星。
Objective To investigate the clinical efficacy of moxifloxacin regimen in the treatment of extensively drug-resistant pulmonary tuberculosis. Methods 85 cases of drug-resistant smear, drug susceptibility test results of levofloxacin, sensitive to sodium ammonia salicylate, and all other drug-resistant patients were randomly divided into treatment group and control group, with the exception of levofloxacin and moxifloxacin other than the same medication. Results The negative conversion rates of sputum in the treatment group were 41.9%, 60.5%, 88.4% and 95.3% respectively in the first, second, third, sixth, sixth and eighteen months. The sputum negative conversion rates in the control group were 14.3%, 31.0%, 57.1% and 71.4 %. The void closure rates were 97.7% and 85.7% (P <0.05), respectively, with significant difference (P <0.05). Conclusion Moxifloxacin is superior to levofloxacin in treating MDR-TB.